Overview: Hyaluronic Acid TestIntroduction: The Hyaluronic Acid Test measures hyaluronic acid to assess liver fibrosis or joint disorders, helping diagnose conditions causing liver damage or joint pain. Affecting 1 in 1,000 people with liver disease, hyaluronic acid elevation poses diagnostic challenges due to chronic progression. Following 2023 American Association for the Study of Liver Diseases (AASLD) guidelines, it uses ELISA for high accuracy, supporting biochemistry screening. This test is essential for diagnosis, monitoring, and improving outcomes in hepatology and rheumatology.
Other Names: Hyaluronic Acid Level Test, Fibrosis Marker Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Hyaluronic acid testing began in the 1980s with research by Engström-Laurent, who linked it to liver fibrosis. ELISA advancements in the 1990s by R&D Systems improved detection, surpassing earlier radioimmunoassay methods.
Purpose: Measures hyaluronic acid levels to diagnose liver fibrosis or joint disorders, guides therapy or monitoring, and evaluates patients with liver issues, aiming to prevent complications.
Test Parameters: Hyaluronic acid levels
Pretest Condition: No special preparation required. Collect serum or plasma. Report history of liver or joint issues.
Specimen: Serum (SST, 2-5 mL), Plasma (NaHep, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document liver issues or joint pain. Include current medications or alcohol use.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., cirrhosis), and sample collection risks.
Procedural Considerations: Uses ELISA to measure hyaluronic acid, requiring labs with plate readers. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels confirm fibrosis or joint disease, guiding therapy. Early intervention might prevent progression, while untreated cases lead to worsening. Normal levels may require imaging.
Specialist Consultation: Consult a hepatologist or rheumatologist for interpretation.
Additional Supporting Tests: Liver function test, ultrasound, or joint imaging to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with symptoms needed. False negatives possible with early disease.
References: AASLD Guidelines, 2023; Hepatology, Engström-Laurent A, 2022.
